We are very happy to report that our Excellence in HIV/AIDS Health Care program is continuing very successfully! The doctor from one of the leading health centers in Accra that we have contracted to treat the 15 patients involved in this program has now made 2 visits to us here in Kpando, Ghana.
The doctor’s second visit was in mid-December, he was able to give a more thorough evaluation to all 15 participants in the program as we had the lab results ready that he had requested. For many of the patients seen it was the first time they had ever had a liver function tests done and the results were quiet illuminating.
We now have received the medicine donated by Gilead Sciences. This means we have a 6 month supply of generic Atripla, generic Truvada and Nevirapine. The participants in the EHAHC program will start on this new medication when the doctor makes his third visit in mid-January. Getting the medication to Ghana was a bit challenging but entirely worth it as this anti-retro viral therapy has the potential to allow these 15 patients many more years of quality life.
We are now working to get an additional 6 months of the medication; we are starting early on this process as it is crucial for the health of the patients and success of the anti-retro viral therapy that there are no interruptions in the supply of the medication.
We have raised a total of $7,754USD on GlobalGiving for this project and have only $246USD left to raise to fund this project for an entire year!
Thank you once again for supporting this project which is giving 15 people in late stage AIDS a new lease on life.
Project Reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.
If you donate to this project or have donated to this project, you will get an e-mail when this project posts a report. You can also subscribe for reports via e-mail without donating or by subscribing to this project's RSS feed.